Close menu




October 24th, 2022 | 12:17 CEST

US equities reporting season: Netflix, Snap, Meta Platforms, Aspermont - Will it continue explosively?

  • Technology
  • Investments
  • fintech
Photo credits: pixabay.com

In October, the reporting season for the 3rd quarter started in the USA. This is a highly exciting time, as moves of up to 25% or more are not uncommon when a NASDAQ stock grossly deviates from its guidance. After years of bliss in the tech sector, a new parameter has also crept into the valuation of growth stocks: Interest rates. Discounted future cash flows represent the value of a stock today. If these are adjusted downward and valued at a higher discount due to increased interest rates, this can trigger significant price corrections in an emergency. Of course, this scenario also applies to upside surprises - a reason for further research.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: NETFLIX INC. DL-_001 | US64110L1061 , SNAP INC. CL.A DL-_00001 | US83304A1060

Table of contents:


    Good and bad - Netflix and Snap have delivered

    In the last week, the first values have already been presented. As always, there was good news and bad. At Netflix, the lights have been green again since October 19. Thanks, in part, to the success of series such as "Stranger Things" and "Dahmer", the number of users in the past quarter rose worldwide by 2.4 to a total of 223.1 million. Analysts had only expected an increase of around 1 million. The Company is targeting 4.5 million new contracts for the full year. In the first half of the year, Netflix had lost 1.2 million customers as pressure from competitors such as Amazon Prime and Disney Plus grew. The NFLX share has had one of its strongest weeks, gaining 38% in October alone. With a market cap of USD 128 billion, revenue is again valued at a factor of 4, and the 2023 P/E ratio is 27.5. There is already a lot of hope for good business priced in here.

    Things went differently for Snap. The social media platform reported on the 4th quarter and on an annual basis achieved only slightly increased sales of USD 1.13 compared to USD 1.07 billion. The bottom line was a sharply higher loss of USD 359.5, up from USD 71.9 million a year earlier. Overall, this showed Snap's slowest revenue growth to date since its 2017 IPO. The Company has its work cut out for it against rivals like TikTok as it goes after the all-important online advertising revenue pie. Young users have been favoring Chinese provider TikTok more for the last 2 years when it comes to sharing funny snapshots. The Snap share price plummeted by almost 29% after the announcement, and now the Company wants to buy back its own shares in a volume of up to USD 500 million. The stock now costs only USD 7.9 and has already accumulated an 88% price loss in 12 months.

    Aspermont Ltd. - Strong demand after the European roadshow

    Australian fintech company Aspermont Ltd. is doing much better, with shares still up 4.5% since the start of 2022, despite global stock markets losing as much as 30%. The Perth-based group is a media and fintech company rolled into one. Its core business still historically includes print media, but in its new core sectors, Aspermont is highly modern and provides over 4 million customers with specially tailored data and financial services.

    Based on a XaaS model, Aspermont offers an audience-client ecosystem that flexibly adapts to the needs of each recipient. Within a large network of information transmitters, exclusive news and data about the global raw materials industry are made available to a broad community of interested parties and investors within a B2B approach. The contacts are also used on the "Blu Horseshoe" platform to place and broker investor capital, and the volume of business requested here is increasing from quarter to quarter. The operational trend at Aspermont is convincing, as the 2022 half-year revenue has increased from AUD 7.3 million to AUD 9.3 million, and the available liquidity has grown to AUD 6.6 million.

    At a major European roadshow in September, the Company was able to attract many new investors, stock exchange turnover rose sharply, and the share price increased by around 50%. Due to the strong growth potential, the analyst firm GBC sees a price target of AUD 0.11 or EUR 0.08 on a 14-month horizon and rates the stock a buy. At a current price of EUR 0.016, this represents a fivefold potential. The exchange Tradegate offers risk-conscious investors very good liquidity in the share, but always order it with a limit.

    Meta Platforms, Amazon & Co - The week of FAANGs

    As of today, things are getting really exciting. The largest technology companies in the world are opening their books for the past quarter. For the NASDAQ and especially the DAX as a "follower", this is of particular importance and should also decide in the short term on the continuation of the correction. From a purely technical point of view, there were already positive divergent signals last week in favor of a breather to the upside.

    According to research by Barron's, the market value of the reporting companies adds up to around 25% of the capitalization of the world's heaviest index, the S&P 500. What is explosive here is that the reporting companies can adjust their outlook for 2022 for the last time and certainly also formulate an expectation for 2023. Statements on next year are likely to be very difficult, as the global economic slump and galloping inflation could weigh heavily on the consumption and investment budgets of private individuals and companies. The technology sector is also suffering from rising interest rates and the strong US dollar.

    Facebook operator Meta Platforms will report its results on October 26. The Company itself expects total revenues in a broad range of USD 26 billion to USD 28.5 billion for the latest quarter. The consensus estimate of polled analysts is USD 27.44 billion, representing a 5.4% decline from the same quarter a year ago. Accordingly, earnings per share are expected to be USD 1.82, more than 40% lower than in Q3-2021. Maybe it will not be so bad after all - the only thing that helps is to buckle up!


    The sell-off on the stock markets stopped last Friday ad hoc and sent the NASDAQ brilliantly upwards with an intraday reversal. Perhaps this is a harbinger of positive surprises in the FAANG stocks. They are all not cheap, but the valuation is already significantly lower than at the beginning of the year. The small Aspermont Ltd. has been able to surprise positively so far in 2022 and continues to grow!


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 29th, 2026 | 07:30 CEST

    AI and M&A Frenzy in the Life Sciences Sector: Bayer, Vidac Pharma, Novo Nordisk, Evotec, and Eli Lilly

    • Biotechnology
    • Pharma
    • Biotech
    • AI
    • Investments

    Yes, you read that correctly. Pharmaceutical companies are actively embracing artificial intelligence (AI) and, thanks to lower costs, better validation, and faster study setups, could emerge as winners of the new AI wave in the medium term. Many stocks in the life sciences sector had been overlooked by the market, but investors are now taking notice again. Eli Lilly is betting on AI and expanding its portfolio through targeted acquisitions, including the takeovers of sleep-wake specialist Centessa Pharmaceuticals and blood cancer specialist Ajax. At Evotec and Vidac Pharma, much of the focus is on cancer, while Novo Nordisk faces stiff competition from Eli Lilly's weight-loss drugs. Then came the welcome news regarding Bayer. The Supreme Court ruled that approximately 181,000 individual lawsuits alleging a lack of warning labels on packaging are no longer legally viable, as the US Environmental Protection Agency (EPA) has classified the herbicide glyphosate as safe. Lots of good news, and plenty of opportunities for active investors - we provide a few insights.

    Read

    Commented by Matthias Schomber on June 26th, 2026 | 07:25 CEST

    SAP Testing the Waters, BYD On the Offensive, and MustGrow Biologics Raises Fresh Capital - Is a Rebound on the Horizon?

    • Agriculture
    • mustard
    • agritech
    • biologicals
    • Electromobility
    • Investments
    • Software

    Created and published on behalf of MustGrow Biologics Corp.

    The winds across global equity markets have grown noticeably stronger, bringing sharp moves in both directions. Technology and automotive giants that have long been accustomed to success are feeling the full force of this turbulence. Faced with declining share prices and geopolitical uncertainty, investors are increasingly looking beyond the mainstream for fresh opportunities. While companies such as SAP and BYD are fighting to defend their lofty valuations, intriguing second-tier players are quietly positioning themselves for growth. This raises a legitimate question: should investors allocate capital into "fallen angels" such as SAP and BYD, or focus on lesser-known growth stories with potentially greater upside? We examine the current market environment and take a closer look at three very different companies. Discover why software heavyweight SAP and electric vehicle pioneer BYD are facing challenges, and why Canadian agtech company MustGrow Biologics could be approaching a breakout. One thing is certain: the stage is set for an exciting summer in the markets.

    Read

    Commented by Matthias Schomber on June 24th, 2026 | 08:35 CEST

    Allianz Breaks the Record, Siemens Energy Is on a Roll, and Is HPQ Silicon on the Verge of a Breakthrough?

    • Silicon
    • Hydrogen
    • renewableenergy
    • Energy
    • Batteries
    • Investments

    The stock market is currently producing stories as different as one could possibly imagine. On one hand, we are witnessing impressive rallies—especially in the AI sector and among AI-related stocks—as well as historic milestones at established German blue-chip companies such as Allianz. Record profits and full order books are pushing share prices to levels unimaginable just a few years ago. On the other hand, smaller technology companies are stepping into the spotlight, aiming to revolutionize entire industries with fresh ideas and smart partnerships. Today, we take a detailed look at this fascinating mix. We examine the rapid resurgence of a true energy heavyweight from Germany: Siemens Energy. We analyze the historic breakout of a Munich-based insurance giant: Allianz. And we highlight a Canadian materials specialist whose stock is approaching a decisive technical level and comes with highly intriguing news flow: HPQ Silicon. Take a moment to explore three completely different investment ideas, each carrying its own potential for excitement—and possibly gains—in your portfolio.

    Read